匯智協和公司 創始人，首席執行官
前強生(J&J)全球創新合作戰略聯盟 全球總監
李秀艷博士專長以多方合作尤其是跨境合作的方式開發上市高價值的醫藥健康產品。她領導的匯智協和專注幫助中國企業國際化，轉讓其產品的國際權益及建立適宜的境外銷售渠道，并幫助中國企業境內境外尋找合適的產品技術或合作伙伴。李秀艷博士獲美國康州大學藥學博士，之前獲北京大學化學系學士和碩士學位。曾任職Honeywell, AMRI, Covidien, J&J 強生，方達，藥明康德等多家國內國外知名企業。 職涯前12年迅速從一線研發科學家成長為跨界產品創新的領軍人，直接領導并參與了多個新藥，仿制藥，大健康產品，輔料，高純試劑及材料的開發，包括生產工藝開發，分析方法開發，中試生產，及大規模生產的技術轉移。中期6年在國際知名的健康產品開發公司強生負責產品的全球外包生產和新劑型產品的創新合作，外包產品價值2.5億美元，合作開發產品管線價值10億美元。得益于與超過200多家的CRDMO， DDS， Biotech and pharma企業的交流訪問及合作，積累了豐富的技術評估，外包或供應商盡職調查，合同洽談的經驗。近5年供職中美著名外包服務企業，領導在中國的產品開發申報的服務，向中國引進先進的醫療健康產品和技術，幫助中國企業國際化，更深刻地理解了中國市場和企業的需求。2015年底合伙創立匯智協和。她還兼任世中聯經皮給藥專業委員會會副主席，兒童產品聯盟籌委會委員。
Dr. Cheryl Li, currently CEO and CO-founder of PharmaSynergy, was honored to have served in several reputable CRDMO, global pharmaceutical and consumer product companies including Wuxi Apptec, J&J, Covidien, AMRI. She has over 20 years in-depth industry experience with increasing responsibilities in a wide range of professional areas including product development (API and FGs), R&D outsourcing, external manufacturing, product in-licensing and strategic partnership, product due diligence, and business contract negotiation. She had assessed more than 200 CRO/CMO and DDS firms as well as API and Packaging companies globally and is familiar with how the businesses are conducted in different parts of the world. She received her Ph.D. degree in Pharmaceutical Sciences from UCONN, MS and BS degrees in Chemistry from Peking University. She has been widely involved in various professional organizations, currently serving as VP of China Transdermal Society and the Organizing Committee member for Children’s Products Association.
隆安律師事務所 合伙人/執業律師、專利代理人
隆安律師事務所合伙人/執業律師、專利代理人，魯律師先后就讀于華東政法大學法律學院、上海交通大學藥學院。擁有法學、藥學等領域的復合背景，擅長醫藥領域創新成果知識產權保護、醫藥創新技術成果轉化、醫藥項目投融資及CFDA/FDA政策咨詢等。曾主持某505B(2)新藥項目的投融資及中美雙報評估；主辦某藥品配方商業秘密侵權案（涉案標的約1億）、某創新生物藥企基因測序專利技術B輪融資項目（融資規模1.2億）、上海交大某創新制劑專利復審、某上市公司知識產權戰略規劃等；并為多家醫藥上市公司進行國際專利布局，為國內外多家高科技企業提供知識產權保護及投融資服務，具有多家新藥高科技初創公司成果轉化及融資經驗。
隆安成立于1992年，是中國最早的合伙制律師事務所之一, 現有員工人數約1200人。在過去的二十五年里，隆安為包括世界500強在內的眾多大中型企業提供了并購、金融、外商直接投資、知識產權、大型項目等領域的法律服務。隆安多次被全國律師管理機構評為中國最為優秀的律師事務所之一。憑借近年來的整體實力，隆安成功入圍《亞洲法律雜志》年度多項法律大獎，入選中國十佳成長律所，并以前十的成績榮登亞洲最大50家律所及中國律所30強榜單。隆安亦在英國《律師》雜志亞太地區百強律所榜單及中國精英律所30強榜單中位居前列。
Mr. Lu Liyan is the partner, lawyer and patent lawyer of Long An Law Firm. Lawyer Lu studied law at East China University of Political Science and Law and studied Pharmaceutical Engineering at Shanghai Jiao Tong University, thus possessing a complex background in law and pharmacy. Lawyer Lu is good at protection of intellectual property involving innovative achievements in the field of medicine, transformation of medical innovative technology achievements, investment and financing of pharmaceutical projects and consultation of CFDA / FDA policy. Lawyer Lu has presided over the investment & financing of a 505B (2) new drug project as well as the evaluation conference of the US-Chinese Application regarding the new drug; has dealt with an infringement of commercial secret regarding a drug formulation; has undertook a B round of financing regarding an innovative biopharmaceutical company's gene sequencing patent; has acted for the reexamination of an innovative formulations patent of Shanghai Jiao Tong University; has designed the intellectual property strategic planning of a listed company; has designed the international patent portfolio for many listed pharmaceutical companies; has been providing services involving the protection of intellectual property and investment & financing for many high-tech enterprises at home and abroad; and experienced in financing and transforming the achievements of many newly established high-tech companies.